Compare DXLG & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DXLG | MRKR |
|---|---|---|
| Founded | 1976 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.5M | 27.7M |
| IPO Year | 1994 | 2010 |
| Metric | DXLG | MRKR |
|---|---|---|
| Price | $0.72 | $1.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $1.50 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 107.9K | 69.6K |
| Earning Date | 05-28-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.61 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $435,017,000.00 | N/A |
| Revenue This Year | $3.85 | N/A |
| Revenue Next Year | $4.09 | $936.27 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.44 | $0.81 |
| 52 Week High | $1.69 | $4.07 |
| Indicator | DXLG | MRKR |
|---|---|---|
| Relative Strength Index (RSI) | 59.10 | 47.32 |
| Support Level | $0.48 | $1.34 |
| Resistance Level | $0.72 | $1.52 |
| Average True Range (ATR) | 0.06 | 0.08 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 49.21 | 34.01 |
Destination XL Group Inc is a retailer of branded and Tall men's clothing and shoes in the United States. It also sells products across the world. The company sells its products under the trade names Destination XL, DXL, DXL Men's Apparel, DXL outlets, Casual Male XL, and Casual Male XL outlets. The company has two principal operating segments: Store and Direct business. The company have two principal operating segments: company's stores and direct business.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: MT-601; and MT-401-OTS.